These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28456840)

  • 1. Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder.
    Peterson K; Dieperink E; Anderson J; Boundy E; Ferguson L; Helfand M
    Psychopharmacology (Berl); 2017 Jun; 234(11):1649-1661. PubMed ID: 28456840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder? A Systematic Review of Clinical Trials and Cost-Effectiveness Studies.
    Rosenblat JD; Lee Y; McIntyre RS
    J Clin Psychiatry; 2017 Jun; 78(6):720-729. PubMed ID: 28068459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis.
    Rosenblat JD; Lee Y; McIntyre RS
    J Affect Disord; 2018 Dec; 241():484-491. PubMed ID: 30149336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomic Testing for Psychotropic Medication Selection: A Systematic Review of the Assurex GeneSight Psychotropic Test.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2017; 17(4):1-39. PubMed ID: 28515818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study.
    Perlis RH; Patrick A; Smoller JW; Wang PS
    Neuropsychopharmacology; 2009 Sep; 34(10):2227-36. PubMed ID: 19494805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders.
    Serretti A; Olgiati P; Bajo E; Bigelli M; De Ronchi D
    World J Biol Psychiatry; 2011 Oct; 12(7):501-15. PubMed ID: 21595526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.
    Altar CA; Carhart JM; Allen JD; Hall-Flavin DK; Dechairo BM; Winner JG
    Pharmacogenomics J; 2015 Oct; 15(5):443-51. PubMed ID: 25686762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT.
    Wang X; Wang C; Zhang Y; An Z
    BMC Psychiatry; 2023 May; 23(1):334. PubMed ID: 37173736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetic studies: a tool to improve antidepressant therapy.
    Ramos M; Berrogain C; Concha J; Lomba L; García CB; Ribate MP
    Drug Metab Pers Ther; 2016 Dec; 31(4):197-204. PubMed ID: 27889704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents.
    Cox GR; Callahan P; Churchill R; Hunot V; Merry SN; Parker AG; Hetrick SE
    Cochrane Database Syst Rev; 2012 Nov; 11():CD008324. PubMed ID: 23152255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder.
    Lin E; Chen PS; Chang HH; Gean PW; Tsai HC; Yang YK; Lu RB
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Oct; 33(7):1167-72. PubMed ID: 19560507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials.
    Bousman CA; Arandjelovic K; Mancuso SG; Eyre HA; Dunlop BW
    Pharmacogenomics; 2019 Jan; 20(1):37-47. PubMed ID: 30520364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits of and Barriers to Pharmacogenomics-Guided Treatment for Major Depressive Disorder.
    Ahmed AT; Weinshilboum R; Frye MA
    Clin Pharmacol Ther; 2018 May; 103(5):767-769. PubMed ID: 29388201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial).
    Berm EJ; Hak E; Postma M; Boshuisen M; Breuning L; Brouwers JR; Dhondt T; Jansen PA; Kok RM; Maring JG; van Marum R; Mulder H; Voshaar RC; Risselada AJ; Venema H; Vleugel L; Wilffert B
    Trials; 2015 Jan; 16():37. PubMed ID: 25636328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications.
    Fabbri C; Serretti A
    Curr Psychiatry Rep; 2015 Jul; 17(7):50. PubMed ID: 25980509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder.
    Winner JG; Carhart JM; Altar CA; Allen JD; Dechairo BM
    Discov Med; 2013 Nov; 16(89):219-27. PubMed ID: 24229738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: Systematic review and meta-analysis of randomised controlled trials.
    Arnone D; Omar O; Arora T; Östlundh L; Ramaraj R; Javaid S; Govender RD; Ali BR; Patrinos GP; Young AH; Stip E
    Neurosci Biobehav Rev; 2023 Jan; 144():104965. PubMed ID: 36463971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial.
    Thase ME; Parikh SV; Rothschild AJ; Dunlop BW; DeBattista C; Conway CR; Forester BP; Mondimore FM; Shelton RC; Macaluso M; Li J; Brown K; Jablonski MR; Greden JF
    J Clin Psychiatry; 2019 Oct; 80(6):. PubMed ID: 31721487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries.
    Olgiati P; Bajo E; Bigelli M; De Ronchi D; Serretti A
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Jan; 36(1):147-54. PubMed ID: 21911028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools.
    Bousman CA; Dunlop BW
    Pharmacogenomics J; 2018 Sep; 18(5):613-622. PubMed ID: 29795409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.